🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

RecruitingPhase 2Ages 19 Years - anyAllUniversity of Miami
NCT04295486 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria: * \> 18 years of age * Planning to undergo a primary total hip or knee arthroplasty Exclusion Criteria: * High risk patients for VTE as defined by: * History of venous thromboembolism * Active malignancy * Known pro thrombotic condition * BMI \> 40 * Patients requiring anticoagulation for pre-existing conditions * Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others. * Patients not fluent in the language of the informed consent form * Prisoners * Pregnancy * Reported to have mental illness or belonging to a vulnerable population
💊

What it tests

  • Aspirin
📍

Where

1 site
University of Miami Hospital
Miami, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy